DE69124415D1 - Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen - Google Patents

Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen

Info

Publication number
DE69124415D1
DE69124415D1 DE69124415T DE69124415T DE69124415D1 DE 69124415 D1 DE69124415 D1 DE 69124415D1 DE 69124415 T DE69124415 T DE 69124415T DE 69124415 T DE69124415 T DE 69124415T DE 69124415 D1 DE69124415 D1 DE 69124415D1
Authority
DE
Germany
Prior art keywords
oxoprostaglandin
dehydroxy
treatment
allergic diseases
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69124415T
Other languages
English (en)
Other versions
DE69124415T2 (de
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of DE69124415D1 publication Critical patent/DE69124415D1/de
Publication of DE69124415T2 publication Critical patent/DE69124415T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE69124415T 1990-04-27 1991-04-24 Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen Expired - Lifetime DE69124415T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11230390 1990-04-27
JP6132791 1991-03-01

Publications (2)

Publication Number Publication Date
DE69124415D1 true DE69124415D1 (de) 1997-03-13
DE69124415T2 DE69124415T2 (de) 1997-05-15

Family

ID=26402368

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69124415T Expired - Lifetime DE69124415T2 (de) 1990-04-27 1991-04-24 Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen

Country Status (10)

Country Link
EP (1) EP0454429B1 (de)
JP (1) JPH07103030B2 (de)
KR (1) KR970005173B1 (de)
AT (1) ATE148344T1 (de)
AU (1) AU639322B2 (de)
CA (1) CA2041240C (de)
DE (1) DE69124415T2 (de)
DK (1) DK0454429T3 (de)
ES (1) ES2099736T3 (de)
GR (1) GR3022706T3 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654339A (en) * 1992-08-07 1997-08-05 Schering Aktiengesellschaft Use of prostane derivatives of formulate I and II for treatment of chronic polyarthritis
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
EP2699244A4 (de) * 2011-04-19 2014-10-22 Sucampo Ag Verfahren zur modulation einer cytokinaktivität
US20120277299A1 (en) * 2011-04-27 2012-11-01 Sucampo Ag Method for modulating ion transporter
US20140212441A1 (en) * 2011-06-21 2014-07-31 R-Tech Ueno, Ltd. Pharmaceutical composition for inflammatory diseases, allergic diseases and autoimmune diseases
WO2015049876A1 (ja) * 2013-10-04 2015-04-09 国立大学法人東北大学 腎機能障害の予防又は改善剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644638A (en) * 1970-08-24 1972-02-22 American Home Prod Compositions and methods for relieving bronchial spasm with prostanoic acids and esters
US3836667A (en) * 1972-03-24 1974-09-17 Miles Lab Method of producing bronchodilation
GB1507211A (en) * 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
EP0153858A3 (de) * 1984-02-29 1985-12-11 The Upjohn Company Therapeutische Anwendung von Protaglandinen
US4879285A (en) * 1986-08-22 1989-11-07 Royal North Shore Hospital And Area Health Service Fertility control
AU616502B2 (en) * 1988-04-22 1991-10-31 Medvet Science Pty. Ltd. Treatment of inflammatory disorders in humans
DE69025787T2 (de) * 1989-04-04 1996-10-31 Beiersdorf Ag Mittel zur Atopieprophylaxe
DK0444844T3 (da) * 1990-02-26 1995-04-03 R Tech Ueno Ltd Hidtil ukendte 15-dehydroxy-16-oxoprostaglandiner

Also Published As

Publication number Publication date
GR3022706T3 (en) 1997-05-31
DE69124415T2 (de) 1997-05-15
DK0454429T3 (da) 1997-03-17
AU639322B2 (en) 1993-07-22
JPH07103030B2 (ja) 1995-11-08
ES2099736T3 (es) 1997-06-01
CA2041240A1 (en) 1991-10-28
EP0454429A2 (de) 1991-10-30
KR970005173B1 (ko) 1997-04-14
ATE148344T1 (de) 1997-02-15
JPH04330015A (ja) 1992-11-18
AU7593091A (en) 1991-11-07
EP0454429B1 (de) 1997-01-29
CA2041240C (en) 2001-07-31
EP0454429A3 (en) 1992-07-15
KR910018028A (ko) 1991-11-30

Similar Documents

Publication Publication Date Title
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
ATE143263T1 (de) Behandlung von neurodegenerativen erkrankungen
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
DE69024744D1 (de) Behandlung der hepatobilären Erkrankung mit 15-Ketoprostaglandin-Derivaten
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69123892D1 (de) Behandlung von Katarakt mit prostacyclinverbindungen
AT400095B (de) Zahnärztliches handstück für die behandlung von zähnen mit laserstrahlen
DE69228235D1 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE90565T1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
ATE86857T1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.
ATE98127T1 (de) Verwendung von peroxidlipiden zur herstellung eines arzneimittels zur behandlung von kreislaufinsuffizienz bei lokaler applikation.
DE69001070D1 (de) Verwendung von beta-blockierungsmitteln zur behandlung der meniere-krankheit.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE58476T1 (de) Verwendung von doxaminol zur herstellung eines arzneimittels zur behandlung der peripheren arteriellen verschlusskrankheit.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SUCAMPO AG, ZUG, CH